Report Overview

China Phenylketonuria Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Phenylketonuria is defined as a rare inherited genetic disorder that leads to the increase in levels of phenylalanine in blood. Phenylalanine is an amino acid which is composed of proteins obtained from food and diet. The incidence rate of phenylketonuria in China is 1 in 11,000 births. The currentbirth rateforChinain 2021 is 11.159 births per 1000 people.



Market Drivers

The China is growing market for phenylketonuria due to increasing awareness, growing research in the field of genomics and bioinformatics, changing lifestyle, advancements in the healthcare industry, increase in Chinas incidence rate (1 in 11,000 births) and rising per capita income are expected to drive the phenylketonuria diagnosis and treatment market during the forecast period.

However, there are some restraining factors for the growth of phenylketonuria therapeutics market in China such as overall high cost of treatment, stringent government regulations, and unfavourable reimbursement scenario.